ResultsBusiness Today
Glenmark Pharma shares fall 4% after Q2 profit plunges 57%
GreyOak summary
Glenmark Pharma shares dropped 4% following Q2 results showing a 56.8% fall in profit after tax and a 30% decline in revenue. The drop was driven by a 72.9% fall in North America revenue, though core business growth was noted. Management maintained full-year revenue guidance of Rs 17,000-18,000 crore.
What it affects
- Glenmark PharmaceuticalsGLENMARKNegative -20
Shares fell 4% as Q2 profit plunged 57%Rolling sentiment Negative -54
Source
Read the original at Business TodayMore Glenmark Pharmaceuticals news
- Pharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%Business Standard · Stock view ·
- Motilal Oswal sets Glenmark Pharma target at Rs 3000Moneycontrol · Company update ·
- Pharma stocks rally: Aurobindo, Divi's, Glenmark, Symbiotec hit new highsBusiness Standard · Stock view ·
- Glenmark Pharma shares react to better-than-expected US sales in Q2CNBC-TV18 · Results ·
- Titan, Bharti, Britannia, Glenmark, Godfrey, NCC, KNR, Ashoka focusMoneycontrol · Stock view ·